← Leaderboards
Herve Avet Loiseau
Dana-Farber Cancer Inst
$3,475,894
Attributed
$3,475,894
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $434.3K · FY2011–24$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,475,894 · 6
By mechanism
P01$3,475,894 · 6
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Gordon J Harris$11,607,211
- Marc Vidal$80,344,142
- Jean Zhao$18,430,855
- Piotr Sicinski$42,703,610
- Kenneth C Anderson$25,995,373
Others in their field
Top investigators on “Genomics”
- Eric S Lander · Whitehead Institute For Biomedical Res$790,826,794
- Richard A Gibbs · Baylor College Of Medicine$661,700,875
- Richard K. Wilson · Washington University$497,388,134
- Leonard Freedman · Leidos Biomedical Research, Inc.$405,398,682
- David Heimbrook · Leidos Biomedical Research, Inc.$333,649,126
- Stacey Gabriel · Massachusetts Institute Of Technology$331,896,891
Research focus
GenomicsMultiple MyelomaCancer GenomicsResponseCellsClinical ResearchDoseLenalidomideTransplantationModernizationBortezomibDexamethasoneFundingRandomizedNext GenerationResidual NeoplasmMutationNewly DiagnosedClinically RelevantComplexMonoclonal Gammopathy Of Uncertain SignificanceCohortClinical TrialsSampling
Grant awards (23)
Core 2 - Clinical and Tissue Core$217,429
P01 · FY2024 · CA · contact PI
Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma$189,390
P01 · FY2024 · CA · contact PI
Core 2 - Clinical and Tissue Core$229,219
P01 · FY2023 · CA · contact PI
Project 1: Developing MRD-based therapeutic strategy in newly diagnosed multiple myeloma$179,308
P01 · FY2023 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$186,148
P01 · FY2021 · CA · contact PI
Core 2: Clinical and Tissue Core$169,732
P01 · FY2021 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$186,148
P01 · FY2020 · CA · contact PI
Core 2: Clinical and Tissue Core$169,732
P01 · FY2020 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$186,148
P01 · FY2019 · CA · contact PI
Core 2: Clinical and Tissue Core$169,730
P01 · FY2019 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$186,148
P01 · FY2018 · CA · contact PI
Core 2: Clinical and Tissue Core$169,732
P01 · FY2018 · CA · contact PI
Core 2: Clinical and Tissue Core$29,417
P01 · FY2018 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$29,417
P01 · FY2018 · CA · contact PI
Core 2: Clinical and Tissue Core$9,806
P01 · FY2018 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$9,805
P01 · FY2018 · CA · contact PI
Project 1. Developing MRD-based therapeutic strategy in newly-diagnosed multiple myeloma$184,354
P01 · FY2017 · CA · contact PI
Core 2: Clinical and Tissue Core$167,938
P01 · FY2017 · CA · contact PI
Genomic Analysis to Gain Insights into Novel and Clinically Relevant Mol$160,510
P01 · FY2015 · CA · contact PI
Genomic Analysis to Gain Insights into Novel and Clinically Relevant Mol$155,746
P01 · FY2014 · CA · contact PI
Genomic Analysis to Gain Insights into Novel and Clinically Relevant Mol$147,311
P01 · FY2013 · CA · contact PI
Genomic Analysis to Gain Insights into Novel and Clinically Relevant Mol$160,666
P01 · FY2012 · CA · contact PI
Genomic Analysis to Gain Insights into Novel and Clinically Relevant Mol$182,060
P01 · FY2011 · CA · contact PI